<DOC>
	<DOCNO>NCT01619527</DOCNO>
	<brief_summary>The purpose study evaluate single-dose pharmacokinetics bioequivalence darunavir 800 mg administer fix dose combination relative 2 x 400 mg tablet commercial tablet formulation , presence 150 mg cobicistat , ( feed fast condition ) healthy participant .</brief_summary>
	<brief_title>A Study Assess Bioequivalence Darunavir When Co-Administrated With Cobicistat Under Fed Fasted Conditions</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( people know identity intervention ) , 3-panel , single-center , single-dose , crossover ( method use switch patient one treatment arm another clinical trial ) study 134 healthy adult participant . The study consist 3 phase include screen phase approximately 3 week ( Days -21 -1 ) follow open-label treatment phase consist 3 panel 2 single-dose treatment session 5 day ( Days -1 4 ) separate washout period least 7 day , follow-up period occur 7 10 day last intake study drug . The study consist 3 panel . In panel participant randomly assign 1 2 treatment sequence ( AB BA Panel 1 ; CD DC Panel 2 ; EF FE Panel 3 ) . Participants receive either single-dose darunavir 800 mg 2 x 400 mg tablet cobicistat 150 mg tablet single-dose darunavir/cobicistat 800/150 mg tablet panel ( feed fast condition ) .</detailed_description>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Participant healthy basis physical examination , medical history , vital sign , electrocardiogram clinical laboratory test perform screen Have Body Mass Index ( BMI , weight kg divide square height meter ) 18.5 30.0 kg/m2 , extremes include Men woman must agree use highly effective method birth control Has positive HIV1 HIV2 test screening Has Hepatitis A , B C infection ( confirm hepatitis A antibody immunoglobulin M ( IgM ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody , respectively ) screening Has history renal insufficiency Has history significant skin reaction history allergy drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Cobicistat</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Fixed dose combination</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>Protease inhibitor</keyword>
</DOC>